- Home
- SHOT vs KALA Comparison
SHOT vs KALA Comparison
Compare SHOT & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- KALA
- Stock Information
- Founded
- SHOT 2018
- KALA 2009
- Country
- SHOT United States
- KALA United States
- Employees
- SHOT N/A
- KALA N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- KALA Health Care
- Exchange
- SHOT Nasdaq
- KALA Nasdaq
- Market Cap
- SHOT 31.4M
- KALA 27.3M
- IPO Year
- SHOT 2020
- KALA 2017
- Fundamental
- Price
- SHOT $0.42
- KALA $6.64
- Analyst Decision
- SHOT
- KALA Strong Buy
- Analyst Count
- SHOT 0
- KALA 2
- Target Price
- SHOT N/A
- KALA $15.00
- AVG Volume (30 Days)
- SHOT 583.2K
- KALA 108.1K
- Earning Date
- SHOT 03-31-2025
- KALA 03-28-2025
- Dividend Yield
- SHOT N/A
- KALA N/A
- EPS Growth
- SHOT N/A
- KALA N/A
- EPS
- SHOT N/A
- KALA N/A
- Revenue
- SHOT $652,495.00
- KALA N/A
- Revenue This Year
- SHOT N/A
- KALA N/A
- Revenue Next Year
- SHOT N/A
- KALA N/A
- P/E Ratio
- SHOT N/A
- KALA N/A
- Revenue Growth
- SHOT 68.01
- KALA N/A
- 52 Week Low
- SHOT $0.42
- KALA $4.21
- 52 Week High
- SHOT $2.89
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- SHOT 33.14
- KALA 39.29
- Support Level
- SHOT $0.46
- KALA $6.50
- Resistance Level
- SHOT $0.51
- KALA $8.65
- Average True Range (ATR)
- SHOT 0.04
- KALA 0.90
- MACD
- SHOT 0.01
- KALA -0.43
- Stochastic Oscillator
- SHOT 0.06
- KALA 2.98
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.